KORU Medical (KRMD) Q1 2026 earnings review
Top-Line Momentum Sustained, But Tariffs Pinch Margins
KORU Medical extended its streak of >20% revenue growth, posting a record $11.8M in Q1 (+22% YoY). The growth engine was incredibly balanced: International Core surged 35% on European prefilled syringe conversions, while Pharma Services spiked 166%. Despite this volume strength, profitability metrics were mixed. Gross margins decelerated to 61.5% (down 130 bps YoY) as tariff charges and production timing offset scale efficiencies. Net loss narrowed by 31% to $0.8M, and cash burn was a negligible $0.1M, leaving the balance sheet intact. Management reiterated FY26 guidance, expecting 15-22% revenue growth and full-year positive Adjusted EBITDA.
🐂 Bull Case
Revenue growth is stable and accelerating sequentially across key segments. Outperforming the underlying subcutaneous immunoglobulin (SCIg) market proves KORU is successfully taking market share.
Using only $0.1M in cash during Q1 indicates the company has successfully transitioned out of its cash-incineration phase, ending with $8.8M on the balance sheet.
🐻 Bear Case
Gross margin dropped to 61.5% from 62.8% a year ago. If tariffs and production inefficiencies persist, the robust top-line growth will fail to translate into meaningful bottom-line profitability.
Despite 22% revenue growth, the company still posted an operating loss of $0.86M. Management's guidance focuses on Adjusted EBITDA, masking real-world costs like stock-based compensation.
⚖️ Verdict: 🟢
Bullish. The core thesis—converting international markets to prefilled syringes and capturing US market share—is working flawlessly. The slight gross margin compression is a manageable tradeoff for 22% top-line growth and near-zero cash burn.
Key Themes
International Core Growth Remains an Engine
International sales grew 35.2% YoY to $3.3M, driven by distributor purchases supporting pre-filled syringe (PFS) conversions in a key EU market. This is a stable, multi-quarter trend where European partners shift away from vials, heavily favoring KORU's Freedom system.
Macro Pressures Squeezing Gross Margins
Gross margin decelerated to 61.5% in Q1 from 62.8% a year ago. This contradicts the positive volume narrative. Management specifically cited 'tariff-related charges that did not occur in the prior year period' alongside unfavorable production run amortization, partially offsetting a favorable geographic sales mix.
Pharma Services Reverses the Slump
Pharma services and clinical trials revenue accelerated massively, growing 166% YoY to $0.74M. This segment was an extreme laggard in late 2025. The reversal is driven by higher clinical trial product revenues supporting advancing collaborations.
Platform Innovation: Expanding Beyond Ig
KORU submitted a 510(k) application for the use of the Freedom Infusion System with deferoxamine (an iron chelation therapy). This validates management's strategy to expand the platform's addressable market beyond core immunoglobulins into entirely new large-volume subcutaneous treatments.
Operating Leverage Finally Visible
While revenue grew 22.1%, total operating expenses increased only 11.0%. Management effectively contained R&D and SG&A growth, utilizing lower temporary labor expenses to offset higher legal and stock-compensation fees. This leverage is the primary bridge to achieving FY26 positive Adjusted EBITDA.
Other KPIs
Stable. The company consumed roughly $0.1 million in cash during the quarter, a massive improvement from prior years of heavy burn. The current balance provides ample runway to fund operations without immediate dilution risk.
Stable. Grew 11.7% YoY, heavily driven by new patient starts and consistent market share gains in a healthy U.S. SCIg market. This segment remains the predictable anchor for the business, making up 65.8% of total net revenues.
Guidance
Stable. Reiterated guidance implies a 15% to 22% YoY growth rate. Based on Q1's 22.1% performance, the company is tracking well toward the upper end of this range, suggesting confidence in sustained pipeline conversions through the rest of the year.
Accelerating slightly. Q1 actuals landed at 61.5%. Hitting the midpoint of 62% for the full year requires KORU to absorb or mitigate current tariff headwinds and optimize production efficiency in the coming quarters.
Accelerating. With Q1 cash usage at just -$0.1M and Adjusted EBITDA near breakeven (-$0.01M), achieving full-year positive generation is highly credible, provided there are no unguided CapEx spikes or inventory shocks.
Key Questions
Tariff Mitigation Tactics
Gross margin dropped 130 basis points primarily due to tariffs and production timing. Are there active supply chain diversification or price pass-through strategies planned to defend the 61-63% margin guidance?
Pharma Services Volatility
Pharma Services grew 166% this quarter after steep declines in late 2025. Is this a permanent baseline reset due to Phase III advancements, or should we expect extreme lumpiness in this segment for the rest of 2026?
Deferoxamine Timeline and Economics
With the 510(k) submitted for deferoxamine, what is the expected FDA timeline, and how material is the revenue opportunity for this specific indication in 2026 and 2027?